La Ribavirine, un traitement efficace et sûr contre l`hépatite E

*"CHU"Rangueil"et"CHU"Purpan""Toulouse"–""Hôpital"Cochin,"AP;HP),"Pitié"Salpêtrière"(AP;HP)";"Hôpital"Saint"Eloi"de"
Montpellier";"Hôpital"Foch"de"Suresnes";"CHU"Lyon"et"CHU"de"la"Croix"Rousse"de"Lyon";"Hôpital"Paul"Brousse"(Villejuif,"
AP;HP)";"Hôpital"Lapeyronie"de"Montpellier";"Hôpital"Bretonneau"et"CHU"Trousseau"de"Tours";"CHU"Bordeaux";"
Hôpital"Claude"Huriez"et"CHU"de"Lille";"CHU"Le"Bocage"de"Dijon";"CHU"de"Nantes"
! ! !
La#Ribavirine,#un#traitement#efficace#et#sûr#contre#l’hépatite#E#
"
L’hépatite#E#est#responsable#d’une#inflammation#aiguë#ou#chronique#du#foie.#Il#s’agit#d’une#
maladie# émergente# parfois# mortelle# et# sans# traitement# connu.# Vincent# Mallet,# Stanislas#
Pol# et# leur# équipe# de# l’Institut# Cochin# (Université# Paris# Descartes,# Assistance# Publique# –#
Hôpitaux# de# Paris,# CNRS,# Inserm)# et# des# équipes# hospitalières# françaises*# prouvent#
l’efficacité# d’un# traitement# chez# des# patients# souffrant# d’une# infection# chronique# par# le#
virus# de# l’hépatite# E.# La# Ribavirine,# utilisée# en# monothérapie# pendant# 3# mois# permet# de#
guérir# la# majorité# des# patients.# Ces# travaux# ont# fait# l’objet# d’une# publication# le# 20# mars!
2014#dans#la#revue#The!New!England!Journal!of!Medicine.##
!
"#!$%&'(!)#!*+,-./0%0#!1!#(0!*/!.&#2%3&#!4/'(#!)+,-./0%0#!$%&/*#!)/5(!*#!265)#! #0! 65! #(0%2#! 7'#! *#!
0%#&(!)#!*/!.6.'*/0%65! 265)%/*#!#(0!8!&%(7'#!)+%59#40%65! ./&!4#!$%&'(:! ;%!*/! 2/<6&%0-!)#(!4/(!('&$%#50!
)/5(!*#(!./=(!#5!$6%#!)#!)-$#*6..#2#50>!65!/((%(0#!8!'5#!/'?2#50/0%65!)'!562@&#!)#!4/(!&/..6&0-(!
#5! A&/54#! #0! )/5(! *#(! /'0&#(! ./=(! %5)'(0&%/*%(-(! 6B! *#! $%&'(! (#! 0&/5(2#0! 8! *+,622#! ./&! */!
465(622/0%65! )+/*%2#50(!4650/2%5-(! %5('99%(/22#50!4'%0(!#0!./&!*#! (/5?:! C'(7'D8!.&-(#50>!/'4'5#!
0,-&/.%#!5D#(0!-0/@*%#!.6'&!0&/%0#&!*#(!./0%#50(!/00#%50(!)D,-./0%0#!1:!
"#!$%&'(!)#!*+,-./0%0#!1>!4622#!*#(!/'0&#(!$%&'(!)#(!,-./0%0#(>!.&6$67'#!'5#!%59*/22/0%65!)'!96%#:!
E/5(!(/!96&2#!/%?'F>!*+%59#40%65!.#'0!G0&#!26&0#**#!4,#H!*#(!.#&(655#(!I?-#(>!*#(!9#22#(!#54#%50#(!
#0! 4,#H! *#(! .#&(655#(! 2/*/)#(! )'! 96%#:! J,#H! *#(! .#&(655#(! %22'56)-.&%2-#(! K./0%#50(! ?&#99-(>!
./0%#50(!(6'(!4,%2%60,-&/.%#!6'!.#&(655#(!$%$/50!/$#4!*#!LMNO>!*+%59#40%65!./&!*#!$%&'(!)#!*+,-./0%0#!1!
.#'0!-$6*'#&!$#&(!'5#!,-./0%0#!4,&65%7'#!#0!#50&/P5#&!'5#!4%&&,6(#:!!
#
Vers#un#traitement#contre#l’hépatite#E#
!
"/!Q%@/$%&%5#! #(0!'5! 2-)%4/2#50! .&#(4&%0!.6'&!0&/%0#&!4#&0/%5#(! %59#40%65(!$%&/*#(!&#(.%&/06%&#(!4,#H!
*+#59/50!#0!4#&0/%5#(!9%3$&#(!,-26&&/?%7'#(:!J#00#!26*-4'*#!#(0!-?/*#2#50!'0%*%(-#!)/5(!*#!0&/%0#2#50!
)#!*+,-./0%0#!J:! L%54#50!R/**#0>!.&69#((#'&!8! *+S5%$#&(%0-!T/&%(!E#(4/&0#(!#0! .&/0%4%#5!,6(.%0/*%#&!/'!
(#%5!4#50&#!,6(.%0/*%#&!'5%$#&(%0/%&#!J64,%5!KUTVNTO!#0!W/((%2!X/2/&!.&69#((#'&!8! *+S5%$#&(%0-!T/'*!
;/@/0%#&!#0! .&/0%4%#5! ,6(.%0/*%#&!/'! (#%5! )'! 4#50&#! ,6(.%0/*%#&! '5%$#&(%0/%&#! Q/5?'#%*! /$/%#50!
.&-4-)#22#50! .&6'$-! (65! #99%4/4%0-! 4,#H! )#(! ./0%#50(! %22'56)-.&%2-(! (6'99&/50! )+'5#! %59#40%65!
4,&65%7'#!./&!*#!$%&'(!)#!*+,-./0%0#!1!KR/**#0!L>!W%4/5)!1>!;'*0/5%Y!T>!J,/Y$#0/)H#!J>!Z#((#!;>!Z,#&$#0!
1>! R6'0,65! ">! ;6?5%! T>! T6*! ;:! [&%#9! 4622'5%4/0%65\! 4/(#! &#.6&0(! 69! &%@/$%&%5! 0&#/02#50! 96&! 4,&65%4!
,#./0%0%(!1:!U55!M50#&5!R#):!]^_^!C'*!]^`_abK]O\caVd!#0!X/2/&!W>!Q6(0/%5?!">!U@&/$/5#*!A>!e/&&6'(0#!
J>! ",622#! ;>! 1(.6(%06! ">! [/((#! e>! J6%50/'*0! f>! Q%@#(! E>! W6?%#&! R[>! U*&%4! ">! T#&65! CR>! MH6.#0! C:!
Q%@/$%&%5! Z,#&/.=! M5,%@%0(! L%&/*! Q#.*%4/0%65! 65! T/0%#50(! g%0,! J,&65%4! N#./0%0%(! 1! L%&'(! M59#40%65:!
e/(0&6#50#&6*6?=:!]^_^!W6$`_bdKaO\_h_]VcO.!
"
26/03/2014#

! ! !
E/5(! 4#00#! 56'$#**#! -0')#>! *#(! )655-#(! )#! ad! ./0%#50(! ?&#99-(! /00#%50(! )+,-./0%0#! 1! #0! 0&/%0-(! ./&!
Q%@/$%&%5#!650!-0-!&#4'#%**%#(!)/5(!_b!4#50&#(!)#!0&/5(.*/50/0%65!9&/5i/%(!./&!W/((%2!X/2/&!K)'!JNS!
Q/5?'#%*!)#! Z6'*6'(#O!#0!L%54#50!R/**#0:!"#(!4,#&4,#'&(!4659%&2#50!7'#!j*/!Q%@/$%&%5#!.&#(4&%0#!#5!
26560,-&/.%#! .#5)/50! b! 26%(! #(0! '5! 0&/%0#2#50! #99%4/4#! )#! *+%59#40%65! 4,&65%7'#! ./&! *#! $%&'(! )#!
*+,-./0%0#!1j:!T6'&!*/!2/<6&%0-!)#(!./0%#50(!Kkh!./0%#50(!('&! adO>!*#! $%&'(!&#(0/%0!%5)-0#40/@*#!h!26%(!
/.&3(!*+/&&G0!)'!0&/%0#2#50:!S5#!)'&-#!.*'(!*65?'#!)#!0&/%0#2#50!(#2@*#!.&-9-&/@*#!4,#H!*#(!./0%#50(!
96&0#2#50!%22'56)-.&%2-(!6'!4#'l!4,#H!*#(7'#*(!*#!$%&'(!#(0!)-0#40/@*#!)/5(!*#!(/5?!/.&3(!'5!26%(!
)#!0&/%0#2#50:!"#!(#'*!#99#0!(#465)/%&#!%)#50%9%-!#0!.&-$%(%@*#!)#!*/!Q%@/$%&%5#!-0/%0!*+/5-2%#!7'%!/!-0-!
?-&-#!(/5(!)%99%4'*0-!4,#H!*/!.*'./&0!)#(!./0%#50(:!
«#Ce# travail# est# le# fruit# d’une# véritable# collaboration# entre# de# nombreux# centres# français.# Il# s’agit#
d’une# grande# avancée# dans# le# domaine# )-4*/&#! L%54#50! R/**#0.# Nous# espérons# que# nos# résultats#
ouvriront# une# porte# vers# d’autres# études# prospectives# dessinées# pour# évaluer# l’efficacité# de# la#
Ribavirine#dans#le#cas##de#formes#graves#d’infection#par#le#virus#de#l’hépatite#E,#notamment#dans#les#
pays#du#Sud,#où#il#est#un#véritable#fléau##».#
"
"
"
Publication#:##
Ribavirin#for#Chronic#Hepatitis#E#Virus#Infection#in#Transplant#Recipients#
W/((%2!X/2/&>!C/47'#(!MH6.#0>!;%265/!Z&%.65>!R%4,/#*![%(2'0,>!;6.,%#!N%**/%&#>!C-&m2#!E'26&0%#&>!
;=*$%#!Q/)#55#>!U')&#=!J6%**=>!L/*-&%#!e/&&%?'#>!"6'%(!E+U*0#&64,#>!R/00,%/(!['4,*#&>!"%65#*!J6'H%>!
T/(4/*!"#@&/=>!;#@/(0%#5!E,/&/54=>!U55#!R%5#**6>!R/&=$655#!N6'&2/50>!U55#VR/&%#!Q67'#VU965(6>!
A*6&#54#!U@&/$/5#*>!;0/5%(*/(!T6*>!"%65#*!Q6(0/%5?>!L%54#50!R/**#0!
New#England#Journal#of#Medicine.#2014;370(12):1111`20.#
EfM\!_^:_^ahnW1CR6/_]_a]kh!
!
Contact#chercheur#:##
Vincent#Mallet#
T&69#((#'&!!8!*+S5%$#&(%0-!T/&%(!E#(4/&0#(!#0!.&/0%4%#5!,6(.%0/*%#&!/'!(#%5!)#!*+,m.%0/*!J64,%5!KUTVNTO!
M5(0%0'0!J64,%5!KS5%$#&(%0-!T/&%(!E#(4/&0#(>!JWQ;>!M5(#&2O!
^_!ac!k_!b^!_]!
$%54#50:2/**#0o44,:/.,.:9&!
"
"
"
"
A#propos#de#l’Université#Paris#Descartes#
L’Université#Paris#Descartes,#l’université#des#sciences#de#l’homme#et#de#la#santé#à#Paris.#
U$#4!(#(!d!S5%0-(!)#!A6&2/0%65!#0!)#!Q#4,#&4,#!KSAQO!#0!(65!MSZ>!*+S5%$#&(%0-!T/&%(!E#(4/&0#(!46'$&#!
*+#5(#2@*#!)#(!4655/%((/54#(!#5!(4%#54#(!)#!*+,622#!#0!)#!*/!(/50-:!;#'*#!'5%$#&(%0-!9&/54%*%#55#!&-'5%((/50!
2-)#4%5#>!.,/&2/4%#>!)#50/%&#!#0!2/p#'0%7'#>!(65!.m*#!(/50-!#(0!%50#&5/0%65/*#2#50!&#4655'!.6'&!*/!7'/*%0-!
)#!(#(!96&2/0%65(!#0!*+#l4#**#54#!)#!(/!&#4,#&4,#:!!
!
!
!